SOL Capital Management’s AbbVie ABBV Stock Holding History

SOL Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,350	Closed	-$308K	–	55
2025 Q4	$308K	Sell	1,350 -15	-1%	-$3.42K	0.03%	272
2025 Q3	$316K	Hold	1,365	–	–	0.03%	265
2025 Q2	$253K	Hold	1,365	–	–	0.02%	280
2025 Q1	$286K	Hold	1,365	–	–	0.03%	269
2024 Q4	$243K	Hold	1,365	–	–	0.03%	282
2024 Q3	$270K	Hold	1,365	–	–	0.03%	273
2024 Q2	$234K	Hold	1,365	–	–	0.03%	278
2024 Q1	$249K	Hold	1,365	–	–	0.03%	278
2023 Q4	$212K	Buy	1,365 +15	+1%	+$2.19K	0.03%	286
2023 Q3	$201K	Sell	1,350 -300	-18%	-$44K	0.03%	284
2023 Q2	$222K	Buy	1,650 +171	+12%	+$25.1K	0.03%	267
2023 Q1	$236K	Hold	1,479	–	–	0.04%	265
2022 Q4	$239K	Buy	+1,479	New	+$227K	0.04%	258
2022 Q3	–	Sell	-1,479	Closed	-$227K	–	266
2022 Q2	$227K	Hold	1,479	–	–	0.05%	243
2022 Q1	$240K	Sell	1,479 -172	-10%	-$25K	0.04%	244
2021 Q4	$224K	Buy	+1,651	New	+$195K	0.04%	244

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SOL Capital Management's ABBV Position: Q1 2026 in Review

SOL Capital Management sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 1,350 shares — an estimated $308K sold.

SOL Capital Management first reported a position in ABBV in Q4 2021 and held it in 16 quarters. The position peaked at $316K in Q3 2025. 4,104 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

SOL Capital Management reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
SOL Capital Management sold 1,350 AbbVie shares in Q1 2026, an estimated $308K.
SOL Capital Management first reported a position in AbbVie in Q4 2021 and held it in 16 quarters.
SOL Capital Management's AbbVie position peaked at $316K in Q3 2025.
4,104 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on SOL Capital Management's 13F filing for Q1 2026, filed 24 Apr 2026.